达雷妥尤单抗-话题@MedSci

#达雷妥尤单抗#

1篇内容 | 2112人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2188739, encodeId=fb612188e39c8, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=a4671201218' target=_blank style='color:#2F92EE;'>#MM#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=1bf011141e3e' target=_blank style='color:#2F92EE;'>#塞利尼索#</a>, objectTitle=【Haematologica】塞利尼索+达雷妥尤单抗+Vd治疗RRMM的II期研究, objectType=article, longId=814080, objectId=882f81408000, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=882f81408000, replyNumber=0, likeNumber=124, createdTime=2024-02-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=882f81408000, moduleTitle=【Haematologica】塞利尼索+达雷妥尤单抗+Vd治疗RRMM的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=882f81408000)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2177467, encodeId=b3f921e7467fc, content=<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS, objectType=article, longId=806561, objectId=31fe806561d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-filling-form-U2MAYRK.jpg, objectUrl=/article/show_article.do?id=31fe806561d8, replyNumber=0, likeNumber=108, createdTime=2023-12-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=31fe806561d8, moduleTitle=2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31fe806561d8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175858, encodeId=250221e5858dc, content=<a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=2e1610881935' target=_blank style='color:#2F92EE;'>#高危多发性骨髓瘤#</a>, objectTitle=Blood Adv：两项3期研究的事后分析，早期复发MM可获益于达雷妥尤单抗, objectType=article, longId=804166, objectId=e5d2804166d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=e5d2804166d8, replyNumber=0, likeNumber=81, createdTime=2023-12-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e5d2804166d8, moduleTitle=Blood Adv：两项3期研究的事后分析，早期复发MM可获益于达雷妥尤单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5d2804166d8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1222743, encodeId=b9181222e43e6, content=<a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a>+<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>一线治疗不适移植的<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>的疗效可期！, objectTitle=Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！, objectType=article, longId=218592, objectId=454b218592dd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211015/1634282603340_2570354.jpg, objectUrl=/article/show_article.do?id=454b218592dd, replyNumber=0, likeNumber=160, createdTime=2022-05-27, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=454b218592dd, moduleTitle=Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=454b218592dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

达雷妥尤单抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #MM# #地塞米松# #达雷妥尤单抗# #塞利尼索#

【Haematologica】塞利尼索+达雷妥尤单抗+Vd治疗RRMM的II期研究

2024-02-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#地塞米松# #泊马度胺# #达雷妥尤单抗# #RRMM#

2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS

2023-12-27发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#达雷妥尤单抗# #高危多发性骨髓瘤#

Blood Adv：两项3期研究的事后分析，早期复发MM可获益于达雷妥尤单抗

2023-12-19发表于上海

清风徐来2022 (审核中...)

前往app查看评论内容

#达雷妥尤单抗#+#来那度胺#一线治疗不适移植的#多发性骨髓瘤#的疗效可期！

Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！

2022-05-27

科室
- - 订阅+
  - 更多科室
工具
服务